Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + bortezomib + sitagliptin
- Development stage
- Unknown
- Lead developer
- Northwell Health
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
Post-transplant cyclophosphamide + bortezomib + sitagliptin is an investigational combination regimen being evaluated for the prevention of graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The regimen utilizes three distinct mechanisms: cyclophosphamide acts as an alkylating agent to selectively deplete alloreactive T cells post-transplant; bortezomib is a proteasome inhibitor that modulates cytokine signaling and induces apoptosis in alloreactive cells; and sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is hypothesized to enhance regulatory T cell activity and improve hematopoietic engraftment. This combination is being studied by Northwell Health as a calcineurin inhibitor-free and mTOR inhibitor-free prophylaxis strategy for adults with hematologic malignancies receiving reduced-intensity conditioning transplants.
- Other names
- post-transplant cyclophosphamide + bortezomib + sitagliptinPTCy + bortezomib + sitagliptin
02
Targets
DNADPP-4 (Dipeptidyl Peptidase-IV)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on cyclophosphamide + bortezomib + sitagliptin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + bortezomib + sitagliptin.